Phospholipase A and acyltransferase 2 (PLAAT2) (PLAAT2)

Phospholipase A and acyltransferase 2 (PLAAT2), also known as HRAS-like suppressor 2 (HRASLS2), is an enzyme that plays a pivotal role in phospholipid metabolism and cellular signaling (UniProt: Q9NWW9). It belongs to the PLAAT family and exhibits both calcium-independent phospholipase A1/2 and O-acyltransferase activities, which are essential for the remodeling of membrane phospholipids and the generation of lipid mediators (PubMed: 20303980). PLAAT2 is specifically involved in the synthesis of N-acylphosphatidylethanolamines (NAPEs), which serve as precursors to bioactive N-acylethanolamines such as anandamide (PubMed: 19047357). In clinical research, PLAAT2 is recognized for its potential role as a tumor suppressor, as its expression is frequently downregulated in various cancers, including renal and colorectal malignancies (NCBI Gene: 54910). Targeting PLAAT2 mRNA via RNA interference (RNAi) or antisense oligonucleotides represents a potential therapeutic strategy to modulate its expression in diseases where lipid dysregulation or oncogenic signaling is prevalent. Additionally, its role in organelle maintenance, specifically pexophagy, suggests broader implications in metabolic health and aging. While it is an emerging area of interest for therapeutic intervention, specific clinical-stage drugs targeting PLAAT2 are currently limited.

Other names

HRASLS2HRAS-like suppressor 2PLA2G16LH-rev107-like protein 2PLAAT2 mRNA

Degradation of target mRNA via RNA interference or antisense oligonucleotides; inhibition of phospholipase and acyltransferase enzymatic activity.